EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are increasingly available and are used in the treatment of patients with non-small cell lung carcinoma (NSCLC) harboring EGFR-activating mutations1, but acquired resistance to TKIs is a growing problem that leads to a poor prognosis2.